

# Yogesh S Jethava

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8013136/publications.pdf>

Version: 2024-02-01

49  
papers

490  
citations

840119

11  
h-index

713013

21  
g-index

50  
all docs

50  
docs citations

50  
times ranked

959  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
2	Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. <i>Journal of Clinical Investigation</i> , 2018, 128, 2877-2893.	3.9	61
3	Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. <i>Hematology</i> , 2018, 23, 17-24.	0.7	45
4	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). <i>Haematologica</i> , 2015, 100, 1214-1221.	1.7	44
5	Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 111213-111224.	0.8	35
6	Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 507-515.	3.0	33
7	Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 8-9.	0.6	26
8	Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1777-1777.	0.6	23
9	Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3621.	1.8	17
10	Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML. <i>Blood</i> , 2016, 128, 3983-3983.	0.6	17
11	Acquired Agranulocytosis and Factor XI Deficiency in Association With Thymoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e604-e606.	0.8	13
12	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. <i>Clinical Cancer Research</i> , 2017, 23, 2665-2672.	3.2	13
13	Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 47-56.	0.6	7
14	Approach to a patient with cardiac amyloidosis. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 567-574.	0.2	7
15	Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. <i>Blood</i> , 2014, 124, 3409-3409.	0.6	5
16	Cytomegalovirus appendicitis after hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2017, 19, e12747.	0.7	4
17	Case Studies in Physiology: Untangling the cause of hypoxemia in a patient with obesity with acute leukemia. <i>Journal of Applied Physiology</i> , 2021, 131, 788-793.	1.2	4
18	Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4). <i>Blood</i> , 2014, 124, 1199-1199.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. <i>Blood</i> , 2014, 124, 4775-4775.	0.6	4
20	Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. <i>Blood</i> , 2014, 124, 3418-3418.	0.6	3
21	Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 183-192.	0.2	2
22	Transplantation for Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 227-250.	0.2	2
23	A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 552-556.	0.5	2
24	The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. <i>Blood</i> , 2015, 126, 1806-1806.	0.6	2
25	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. <i>Blood</i> , 2015, 126, 2979-2979.	0.6	2
26	Trends in hospitalization outcomes of elderly patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia/myelodysplastic syndrome (AML/MDS).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7044-7044.	0.8	2
27	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3181-3181.	0.6	2
28	Drug Combinations with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 377, 91-94.	13.9	1
29	Wearable Monitors Facilitate Exercise in Adult and Pediatric Stem Cell Transplant. <i>Exercise and Sport Sciences Reviews</i> , 2021, 49, 205-212.	1.6	1
30	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2014, 124, 2128-2128.	0.6	1
31	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. <i>Blood</i> , 2015, 126, 3182-3182.	0.6	1
32	Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis. <i>Blood</i> , 2016, 128, 5594-5594.	0.6	1
33	Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma. <i>Blood</i> , 2019, 134, 3059-3059.	0.6	1
34	Primary CNS high-grade B-cell lymphoma, with rearrangements of MYC and BCL6 : a case report. <i>Blood Research</i> , 2018, 53, 87.	0.5	0
35	Minimal residual disease in multiple myeloma: are we there yet?. <i>International Journal of Hematologic Oncology</i> , 2020, 9, IJH29.	0.7	0
36	A case of immune thrombocytopenic purpura secondary to endometriosis causing a pelvic haematoma. <i>BMJ Case Reports</i> , 2011, 2011, bcr0920103329-bcr0920103329.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP).. Journal of Clinical Oncology, 2014, 32, 8604-8604.	0.8	0
38	Survival outcomes of primary myelodysplastic syndrome in United States.. Journal of Clinical Oncology, 2014, 32, 7112-7112.	0.8	0
39	Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma. Blood, 2014, 124, 2079-2079.	0.6	0
40	Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt. Blood, 2014, 124, 2078-2078.	0.6	0
41	Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival. Blood, 2014, 124, 2012-2012.	0.6	0
42	PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients. Blood, 2014, 124, 3407-3407.	0.6	0
43	Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study. Blood, 2014, 124, 5770-5770.	0.6	0
44	Outcomes of primary plasmacytoma (PP) in United States (US).. Journal of Clinical Oncology, 2015, 33, 8597-8597.	0.8	0
45	Incidence and survival of chronic myelomonocytic leukemia (CMML) in the United States (US).. Journal of Clinical Oncology, 2015, 33, e18072-e18072.	0.8	0
46	Impact of total therapies on clinical outcome of myeloma stratified by risk and molecular subgroups.. Journal of Clinical Oncology, 2015, 33, 8586-8586.	0.8	0
47	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. Blood, 2015, 126, 4193-4193.	0.6	0
48	Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States. Blood, 2016, 128, 4782-4782.	0.6	0
49	Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma. Blood, 2019, 134, 5538-5538.	0.6	0